Stock BHC BAUSCH HEALTH COMPANIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bausch Health Companies Inc. Toronto S.E.

Equities

BHC

CA0717341071

Delayed Toronto S.E.
Other stock markets
 11:11:55 2024-07-11 am EDT 		5-day change 1st Jan Change
10.16 CAD +1.80% Intraday chart for Bausch Health Companies Inc. +6.83% -4.42%
Jul. 10 Raymond James Initiates Bausch Health at Market Perform Rating MT
Jun. 21 Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company sustains low margins.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BAUSCH HEALTH COMPANIES INC. Stock Bausch Health Companies Inc.
-4.42% 2.68B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.49% 846B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.56% 628B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.52% 360B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.47% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.96% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.09% 240B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.07% 224B
A+
NOVARTIS AG Stock Novartis AG
+17.06% 223B
B-
AMGEN INC. Stock Amgen Inc.
+13.14% 173B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BHC Stock
  4. BHC Stock
  5. Ratings Bausch Health Companies Inc.